The blood brain barrier's (BBB) unique endothelial cells and tight junctions selectively regulate passage of molecules to the central nervous system (CNS) to prevent pathogen entry and maintain neural homeostasis. Various neurological conditions and neurodegenerative diseases benefit from small molecules capable of BBB penetration (BBBP) to elicit a therapeutic effect. Predicting BBBP often involves in silico assessment of molecular properties such as lipophilicity (log P ) and polar surface area (PSA) using the CNS multiparameter optimization (MPO) method. This study curated an open-source dataset to benchmark rigorously machine learning (ML) and neural network (NN) models with each other and with MPO for predicting BBBP. Our analysis demonstrated that AI models, especially attentive NNs using stereochemical features, significantly outperform MPO in predicting BBBP. An attentive graph neural network (GNN), we refer to as CANDID-CNS™, achieved a 0.23-0.26 higher AUROC score than MPO on full test sets, and a 0.17-0.19 higher score on stereoisomers filtered subsets. Regarding stereoisomers that differ in BBBP, which MPO cannot distinguish, attentive GNNs correctly classify these with AUROC and MCC metrics comparable to or better than MPO's AUROC and MCC on less difficult test molecules. These findings suggest that integrating attentive GNN models into pharmaceutical drug discovery processes can substantially improve prediction rates, and thereby reduce the timeline, cost, and increase probability of success of designing brain penetrant therapeutics for the treatment of a wide variety of neurological and neurodegenerative diseases.